Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriMix-DC and Ipilimumab in Advanced Melanoma
NCT01302496Phase 2Completed
- Sponsor
- Bart Neyns
- Start
- Feb 2011
- Primary completion
- Oct 2013
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of TriMix-DC in Malignant Melanoma (MM), sponsored by Bart Neyns. Started Feb 2011; status: completed.
02
Drugs
TriMix-DC
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01302496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302496.